ORIONS Money Stocks

[AugustaFriends]

ZLCS the next ACAD - News Article..

Zalicus Is A Promising Biotech With Echoes Of Acadia Pharmaceuticals

Zalicus is developing Z160 as a first in class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker for the treatment of neuropathic and inflammatory pain. Investors are well aware of the 2006 partnership between Merck and Neuromed where Merck licensed the compound (originally named NMED-160) from Neuromed for $25 million upfront and potentially as much as $450 million in milestones and royalties on sales. Merck dissolved the partnership a year later after a phase 2 study showed bioavailability issues. Merck noted that no serious adverse events were seen even at the highest doses. Zalicus then spent the next 7 years correcting the bioavailability issues.

http://seekingalpha.com/article/1705242-zalicus-is-a-promising-biotech-with-echoes-of-acadia-pharmaceuticals?source=yahoo